Organogenesis Story

ORGO -- USA Stock

USD 16.00 0.41 2.50%

Macroaxis Story

Despite quite weak basic indicators, Organogenesis Holdings may actually be approaching a critical reversion point that can send shares even higher in February 2021. The company actively responds to the market. We can now inspect Organogenesis as a potential investment option for your portfolios.

Published over a month ago

View all stories for Organogenesis Holdings | View All Stories

Does Organogenesis Holdings (NASDAQ:ORGO) have persistent basic indicators based on the latest rise?

We provide trade recommendations to complement the recent expert consensus on Organogenesis Holdings. Our dynamic recommendation engine exercises a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time. Organogenesis Holdings dividends can provide a clue to the current value of the stock. The firm is not expected to issue dividends this year as it is trying to preserve or re-invest any of the funds available for distribution to stakeholders.

Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Organogenesis Holdings income statement, its balance sheet, and the statement of cash flows. Potential Organogenesis Holdings investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Organogenesis Holdings investors may use each financial statement separately, they are all related. The changes in Organogenesis Holdings's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Organogenesis Holdings's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

The goal of Organogenesis Holdings fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Organogenesis Holdings performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Organogenesis Holdings shares is the value that is considered the true value of the share. If the intrinsic value Organogenesis is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Organogenesis Holdings.

Please read more on our fundamental analysis page.

Are Organogenesis Holdings Earnings Expected to grow?

The future earnings power of Organogenesis Holdings involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Organogenesis Holdings factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Organogenesis Holdings stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Organogenesis expected earnings.

How Organogenesis utilizes its cash?

To perform a cash flow analysis of Organogenesis Holdings, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Organogenesis Holdings is receiving and how much cash it distributes out in a given period. The Organogenesis Holdings cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Acquisition by Francisco David of 83955 shares of Organogenesis Holdings subject to Rule 16b-3

Legal trades by Organogenesis Holdings insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Organogenesis insider trading alert for grant of stock option (right to buy) by Francisco David, Chief Financial Officer, on 18th of February 2021. This event was filed by Organogenesis Holdings In with SEC on 2021-02-18. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Organogenesis Holdings is not uncomon. Institutional investor usually refers to an organization that invests money in Organogenesis Holdings on behalf of clients or other money managers. Buying and selling of large positions of Organogenesis Holdings stock by institutional investors can create supply and demand imbalances that result in sudden price moves of Organogenesis Holdings stock. Let's take a look at how the ownership of Organogenesis is distributed among investors.

Ownership Allocation

Organogenesis Holdings owns a total of one hundred twenty-seven million seven hundred thousand outstanding shares. Organogenesis Holdings has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how much assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.

Retail Investors

17.01%

Insiders

55.51%

Institutions

27.48%

	Retail Investors	17.01
	Insiders	55.51
	Institutions	27.48

Over 3 percent rise for Organogenesis Holdings. What does it mean for institutional investors?

Latest jensen alpha is at 0.88. Organogenesis Holdings shows above-average downside volatility for the selected time horizon. We advise investors to inspect Organogenesis Holdings further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Organogenesis Holdings future alpha.

Our Final Perspective on Organogenesis Holdings

Whereas many other companies under the drug manufacturers?specialty & generic industry are still a bit expensive, Organogenesis Holdings may offer a potential longer-term growth to institutional investors. With a relatively neutral outlook on the latest economy, it is better to hold off any trading of Organogenesis as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Organogenesis Holdings.

About Contributor

Raphi Shpitalnik is a Junior Member of Macroaxs Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time base at the beginning of the pandemic and eventually acquired a real test for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Organogenesis Holdings. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC